Cardiff Oncology, Inc. - 8-K Filing

Cardiff Oncology increases authorized common stock to 300 million shares and appoints Dr. Leila Alland as interim Chief Medical Officer. (Items: 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On October 22, 2026, the Company filed a Certificate of Amendment to, 7.01 Regulation FD Disclosure)

SEC EDGAR · October 27, 2026, 20:45 UTC

Tickers: $CRDF

Read the full article at SEC EDGAR

Part of the story Cardiff Oncology, Inc. - 8-K Filing (3 articles)

More Regulatory news

Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC